Education
About Us
Working with TipRanks
Follow Us
Wuhan YZY Biopharma Co., Ltd. Class H (HK:2496)
:2496
2496 Stock Chart & Stats
Day’s Range― - ―
52-Week RangeHK$3.02 - HK$8.28
Previous CloseN/A
Volume2.20K
Average Volume (3M)920.00
Market Cap
N/A
Enterprise ValueHK$939.43M
Total Cash (Recent Filing)HK$166.18M
Total Debt (Recent Filing)HK$156.66M
Price to Earnings (P/E)―
Beta0.23
Next Earnings
Mar 27, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.33
Shares Outstanding111,468,810
10 Day Avg. Volume40
30 Day Avg. Volume920
Financial Highlights & Ratios
PEG Ratio0.28
Price to Book (P/B)49.37
Price to Sales (P/S)13.98
P/FCF Ratio-14.75
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$5.50Price Target Upside-19.47% Downside
Rating ConsensusHold
Number of Analyst Covering0
Wuhan YZY Biopharma Co., Ltd. Class H News
2496 FAQ
What was Wuhan YZY Biopharma Co., Ltd. Class H’s price range in the past 12 months?
Wuhan YZY Biopharma Co., Ltd. Class H lowest stock price was HK$3.02 and its highest was HK$8.28 in the past 12 months.
What is Wuhan YZY Biopharma Co., Ltd. Class H’s market cap?
Currently, no data Available
When is Wuhan YZY Biopharma Co., Ltd. Class H’s upcoming earnings report date?
Wuhan YZY Biopharma Co., Ltd. Class H’s upcoming earnings report date is Mar 27, 2026 which is in 164 days.
How were Wuhan YZY Biopharma Co., Ltd. Class H’s earnings last quarter?
Wuhan YZY Biopharma Co., Ltd. Class H released its earnings results on Aug 26, 2025. The company reported -HK$0.326 earnings per share for the quarter, missing the consensus estimate of N/A by -HK$0.326.
Is Wuhan YZY Biopharma Co., Ltd. Class H overvalued?
According to Wall Street analysts Wuhan YZY Biopharma Co., Ltd. Class H’s price is currently Overvalued.
Does Wuhan YZY Biopharma Co., Ltd. Class H pay dividends?
Wuhan YZY Biopharma Co., Ltd. Class H does not currently pay dividends.
What is Wuhan YZY Biopharma Co., Ltd. Class H’s EPS estimate?
Wuhan YZY Biopharma Co., Ltd. Class H’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Wuhan YZY Biopharma Co., Ltd. Class H have?
Wuhan YZY Biopharma Co., Ltd. Class H has 111,468,810 shares outstanding.
What happened to Wuhan YZY Biopharma Co., Ltd. Class H’s price movement after its last earnings report?
Wuhan YZY Biopharma Co., Ltd. Class H reported an EPS of -HK$0.326 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Wuhan YZY Biopharma Co., Ltd. Class H?
Currently, no hedge funds are holding shares in HK:2496
Company Description
Wuhan YZY Biopharma Co., Ltd. Class H
Wuhan YZY Biopharma Co., Ltd., a biotechnology company, develops bispecific antibody-based therapies for the treatment of cancer, cancer-related complications, and age-related eye diseases. It develops various product candidates for the treatment of malignant ascites, malignant pleural effusion, solid tumors, pancreatic cancer, hepatocellular carcinoma and other advanced solid tumors, small cell lung cancer, relapsed/refractory multiple myeloma, and HER2-positive solid tumors; and covid 19 indication, as well as wAMD, DME, and other ocular neovascularization-related diseases. The company was founded in 2010 and is based in Wuhan, China.
Technical Analysis
TOT BIOPHARM International Co. Ltd.
―
JW (Cayman) Therapeutics Co. Ltd.
―
Clover Biopharmaceuticals Ltd.
―
Sirnaomics Ltd.
―
Transcenta Holding Limited
―